CanniMed Therapeutics Inc (TSE:CMED) Director Brenton Harold Zettl acquired 50,000 shares of CanniMed Therapeutics stock in a transaction that occurred on Thursday, June 15th. The shares were purchased at an average cost of C$7.91 per share, for a total transaction of C$395,500.00. 

Brenton Harold Zettl also recently made the following trade(s): 

  • On Wednesday, June 28th, Brenton Harold Zettl purchased 7,300 shares of CanniMed Therapeutics stock. The shares were bought at an average cost of C$7.99 per share, with a total value of C$58,327.00. 
  • On Tuesday, June 27th, Brenton Harold Zettl acquired 7,300 shares of CanniMed Therapeutics stock. The stock was acquired at an average cost of C$7.99 per share, with a total value of C$58,327.00. 

Shares of CanniMed Therapeutics Inc (CMED) opened at 9.45 on Friday. The company’s 50-day moving average is $8.78 and its 200-day moving average is $10.82. CanniMed Therapeutics Inc has a 12-month low of $7.32 and a 12-month high of $13.35. The firm’s market capitalization is $214.58 million.